Literature DB >> 36261765

Protective Effect of Ergothioneine Against Stroke in Rodent Models.

Wei-Yi Ong1,2, Mei-Han Kao3, Wai-Mui Cheung3, Damien Meng-Kiat Leow4,5, Irwin Kee-Mun Cheah5,6, Teng-Nan Lin7.   

Abstract

Ergothioneine (ET) is a naturally occurring antioxidant and cytoprotective agent that is synthesized by fungi and certain bacteria. Recent studies have shown a beneficial effect of ET on neurological functions, including cognition and animal models of depression. The aim of this study is to elucidate a possible effect of ET in rodent models of stroke. Post-ischemic intracerebroventricular (i.c.v.) infusion of ET significantly reduced brain infarct volume by as early as 1 day after infusion in rats, as shown by triphenyltetrazolium chloride (TTC) assay. There was a dose-dependent increase in protection, from 50 to 200 ng of ET infusion. These results suggest that ET could have a protective effect on CNS neurons. We next elucidated the effect of systemic ET on brain infarct volume in mice after stroke. Daily i.p. injection of 35 mg/kg ET (the first dose being administered 3 h after stroke) had no significant effect on infarct volume. However, daily i.p. injections of 70 mg/kg, 100 mg/kg, 125 mg/kg and 150 mg/kg ET, with the first dose administered 3 h after stroke, significantly decreased infarct volume at 7 days after vessel occlusion in mice. In order to elucidate at what time interval during the 7 days there could be effective protection, a second set of experiments was carried out in mice, using one of the effective loading protocols, i.e. 125 mg/kg i.p. ET but the brains were analyzed at 1, 4 and 7 days post-stroke by MRI. We found that ET was already protective against neuronal injury and decreased the size of the brain infarct from as early as 1 day post-stroke. Behavioral experiments carried out on a third set of mice (using 125 mg/kg i.p. ET) showed that this was accompanied by significant improvements in certain behaviors (pole test) at 1 day after stroke. Together, results of this study indicate that i.c.v. and systemic ET are effective in reducing brain infarct volume after stroke in rodent models.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antioxidant; Cerebral ischemia; Ergothioneine; Stroke

Year:  2022        PMID: 36261765     DOI: 10.1007/s12017-022-08727-w

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   4.103


  39 in total

Review 1.  The complexity of neurobiological processes in acute ischemic stroke.

Authors:  R Brouns; P P De Deyn
Journal:  Clin Neurol Neurosurg       Date:  2009-05-14       Impact factor: 1.876

2.  Ergothioneine pretreatment protects the liver from ischemia-reperfusion injury caused by increasing hepatic heat shock protein 70.

Authors:  Abdulkadir Bedirli; Omer Sakrak; Sebahattin Muhtaroglu; Isin Soyuer; Ilkay Guler; Ali Riza Erdogan; Erdogan M Sozuer
Journal:  J Surg Res       Date:  2004-11       Impact factor: 2.192

3.  Ergothioneine produces relaxation in isolated rat aorta by inactivating superoxide anion.

Authors:  G Gokce; M Z Arun
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

4.  Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration?

Authors:  Irwin K Cheah; Lei Feng; Richard M Y Tang; Keith H C Lim; Barry Halliwell
Journal:  Biochem Biophys Res Commun       Date:  2016-07-19       Impact factor: 3.575

5.  The antioxidant action of ergothioneine.

Authors:  D Akanmu; R Cecchini; O I Aruoma; B Halliwell
Journal:  Arch Biochem Biophys       Date:  1991-07       Impact factor: 4.013

6.  Probing the substrate specificity of the ergothioneine transporter with methimazole, hercynine, and organic cations.

Authors:  Silke Grigat; Stephanie Harlfinger; Sonia Pal; Ralph Striebinger; Stefan Golz; Andreas Geerts; Andreas Lazar; Edgar Schömig; Dirk Gründemann
Journal:  Biochem Pharmacol       Date:  2007-04-22       Impact factor: 5.858

Review 7.  Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.

Authors:  D Allan Butterfield; Barry Halliwell
Journal:  Nat Rev Neurosci       Date:  2019-03       Impact factor: 38.755

8.  Improved synthesis of an ergothioneine PET radioligand for imaging oxidative stress in Alzheimer's disease.

Authors:  William J Behof; Clayton A Whitmore; Justin R Haynes; Adam J Rosenberg; Mohammed N Tantawy; Todd E Peterson; Fiona E Harrison; Robert B Beelman; Printha Wijesinghe; Joanne A Matsubara; Wellington Pham
Journal:  FEBS Lett       Date:  2022-02-07       Impact factor: 3.864

Review 9.  Health consequences of improving the content of ergothioneine in the food supply.

Authors:  Robert B Beelman; Allen T Phillips; John P Richie; Djibril M Ba; Sjoerd W Duiker; Michael D Kalaras
Journal:  FEBS Lett       Date:  2022-01-10       Impact factor: 3.864

10.  Ergothioneine, recent developments.

Authors:  Irwin K Cheah; Barry Halliwell
Journal:  Redox Biol       Date:  2021-01-26       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.